Eptifibatide
Also known as: Integrilin
Eptifibatide reversibly blocks the platelet GP IIb/IIIa receptor, preventing fibrinogen and von Willebrand factor from cross-linking platelets and thereby inhibiting the final common pathway of platelet aggregation.
- Drug class
- Glycoprotein IIb/IIIa receptor inhibitor (antiplatelet)
- Primary targets
- Platelet glycoprotein IIb/IIIa receptor (integrin alpha-IIb beta-3)
- Dose reference
- Reference (label/trials, not a recommendation): ACS 180 mcg/kg IV bolus then 2 mcg/kg/min infusion up to 72-96h; PCI 180 mcg/kg bolus, 2 mcg/kg/min infusion, plus a second 180 mcg/kg bolus 10 min later; reduced infusion in renal impairment.
- Half-life
- Approximately 2.5 hours (plasma elimination); platelet function recovers about 4-8 hours after stopping the infusion.
- Developer / origin
- COR Therapeutics (co-developed/marketed with Schering-Plough; later Millennium Pharmaceuticals)
- Reference year
- 1998
- Evidence score
- 5/5 - Strong
Approved uses
- Acute coronary syndrome (unstable angina / non-ST-elevation MI)
- Patients undergoing percutaneous coronary intervention (PCI), including intracoronary stenting
Strong
Eptifibatide is FDA-approved with a deep randomized-trial base. PURSUIT showed a significant ~1.5% absolute reduction in 30-day death/MI in ACS; ESPRIT established the double-bolus PCI regimen (primary endpoint 10.5% to 6.6%). Benefit is real but modest, comes with increased bleeding, and routine early use was not superior in EARLY-ACS.
Approved medication with substantial human clinical evidence.
Evidence basis
- FDA prescribing information (Integrilin/eptifibatide injection, DailyMed)
- PURSUIT trial, NEJM 1998 (~10,900 ACS patients)
- IMPACT-II trial, Lancet 1997 (~4,010 PCI patients)
- ESPRIT trial, Lancet 2000 (coronary stenting, double-bolus regimen)
- EARLY-ACS trial, NEJM 2009 (routine early vs provisional use)
Key references
- New England Journal of MedicineInhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes (PURSUIT, NEJM 1998)
- PubMedNovel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT, Lancet 2000)
- PubMedRandomised placebo-controlled trial of eptifibatide on complications of PCI: IMPACT-II (Lancet 1997)
- New England Journal of MedicineEarly versus delayed, provisional eptifibatide in acute coronary syndromes (EARLY-ACS, NEJM 2009)
- DailyMedEptifibatide injection prescribing information
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Eptifibatide guides
Read the matching guide or adjacent research pages for more context.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Larazotide
Larazotide acetate, AT-1001
An oral, gut-restricted peptide that antagonizes zonulin signaling to limit gluten-driven intestinal tight-junction permeability in celiac disease.
Lanreotide
Somatuline Depot, Somatuline Autogel
Lanreotide binds with high affinity to somatostatin receptors 2 and 5, mimicking native somatostatin to suppress growth hormone, IGF-1 and various neuroendocrine and gut hormones.
Teriparatide
Forteo, Bonsity, PTH 1-34
Once-daily injection produces intermittent activation of the PTH1 receptor on osteoblasts, preferentially stimulating bone formation over resorption to increase bone mass.
Abaloparatide
Tymlos
Abaloparatide is a PTHrP(1-34) analog that agonizes the PTH1 receptor with preference for its transient RG conformation, activating cAMP signaling to stimulate osteoblast-driven new bone formation.